GO
Loading...

Biogen Idec Inc

More

  • US STOCKS-Wall Street rises, biotech shares lead rally Wednesday, 13 Aug 2014 | 2:56 PM ET

    NEW YORK, Aug 13- U.S. stocks rose on Wednesday, with the Dow returning to positive territory for the year as the market shrugged off weak earnings reports and a slump in retail shares. Biotech shares surged, with the Nasdaq biotech index climbing 2.1 percent on the back of stocks including InterMune Inc and Jazz Pharmaceuticals PLC.

  • Biogen, Twitter—and CNBC—take ice bucket challenge Wednesday, 13 Aug 2014 | 12:29 PM ET
    Scott Wapner gets iced after accepting the Ice Bucket Challenge!

    Propelled by Facebook and Twitter, the ice bucket challenge has become a viral sensation. Now Biogen executives and CNBC are rising to the challenge.

  • Costolo accepts CNBC's ice bucket challenge     Tuesday, 12 Aug 2014 | 1:24 PM ET

    CNBC's Scott Wapner accepted the "ice bucket challenge" on "Fast Money Halftime Report." Wapner passed it on to Mark Zuckerberg and Dick Costolo.

  • CNBC's Wapner accepts ice bucket challenge     Tuesday, 12 Aug 2014 | 12:57 PM ET

    CNBC's Scott Wapner accepts the "ice bucket challenge" from Biogen Idec's Doug Williams on "Fast Money Halftime Report." He then passes it to Facebook CEO Mark Zuckerberg and Twitter CEO Dick Costolo. Trader Pete Najarian shares the story of his brother Paul who passed from ALS.

  • Why dying kids can't get the drugs they need Tuesday, 5 Aug 2014 | 7:33 AM ET
    Nathalie Traller back in the clinic.

    Terminally ill patients are increasingly seeking access experimental drugs outside clinical trials, but drug companies often decline these requests. A look at why.

  • July 24- Celgene Corp reported a 25 percent rise in second-quarter profit, edging out Wall Street expectations, but a raised 2014 forecast failed to excite investors and its shares fell nearly 4 percent.

  • Aced the SAT? Try this Cramer question Wednesday, 23 Jul 2014 | 6:19 PM ET

    If you have a penchant for quizzes and such, Jim Cramer thinks this question could lead you to a solid stock idea.

  • *Apple rallies after results, boosting tech names. NEW YORK, July 23- U.S. stocks ended mostly higher on Wednesday, with the S&P 500 closing at a record on Apple's bullish results, though Boeing weighed on the Dow and conflicts in Ukraine and the Gaza Strip kept the broader market's gains in check.

  • U.S. sales of $585 million far exceeded Wall Street forecasts in the $485 million range. The drug is taking flight as patients with the progressive neurological disease move from injectable treatments to more convenient pills, including Novartis AG's Gilenya and Sanofi SA's Aubagio.

  • *Apple rallies after results, boosting tech names. NEW YORK, July 23- U.S. stocks were largely higher on Wednesday, with the S&P 500 hitting another record high after bullish results from tech giants Apple and Microsoft, though technical resistance and conflicts in Ukraine and the Gaza Strip kept gains in check.

  • *Microsoft sees end to Nokia losses, shares rise. NEW YORK, July 23- The S&P 500 hit a record high on Wednesday, lifted by bullish earnings from companies like Apple and Microsoft, though technical resistance and conflicts in Ukraine and the Gaza Strip kept gains in check.

  • As S&P nears 2,000, traders say keep an eye on this Wednesday, 23 Jul 2014 | 9:48 AM ET
    Traders work the floor of the New York Stock Exchange.

    Shaking off geopolitical flare-ups for now, analysts say the S&P 500 is taking aim at the 2,000 level, and the next round of earnings news could help.

  • *Microsoft sees end to Nokia losses, shares rise. NEW YORK, July 23- U.S. stocks were set to rise slightly at the open on Wednesday, boosted by bullish earnings from companies like Boeing, Pepsi and Microsoft, though conflicts in Ukraine and the Gaza Strip weighed on investor confidence.

  • *Microsoft sees end to Nokia losses, shares rise. NEW YORK, July 23- U.S. stock index futures edged up on Wednesday, boosted by bullish earnings from companies like Microsoft and Boeing, though conflicts in Ukraine and the Gaza Strip weighed on investor confidence.

  • Early movers: AAPL, MSFT, BA, DAL, DOW, PEP & more Wednesday, 23 Jul 2014 | 7:57 AM ET

    Some of the names on the move ahead of the open.

  • July 23- Biogen Idec Inc reported sharply higher-than-expected quarterly revenue on surging sales of its new Tecfidera treatment for multiple sclerosis, and the company raised its full-year profit forecast. U.S. sales of $585 million blew past Wall Street expectations in the $485 million range.

  • Biogen revenue trounces forecast as MS drug sales surge Wednesday, 23 Jul 2014 | 7:04 AM ET

    July 23- Biogen Idec Inc reported sharply higher-than-expected quarterly revenue on surging sales of its new Tecfidera oral treatment for multiple sclerosis, and the company raised its full-year profit forecast. The company on Wednesday said it had earned $723.1 million, or $3.01 per share, in the second quarter.

  • Politics fade as earnings take over Friday, 18 Jul 2014 | 6:30 PM ET
    Espirito Santo International is the parent company of several institutions, including Banco Espirito Santo.

    Even as traders monitor the world's hot spots, corporate earnings news could be a positive for stocks in the week ahead.

  • UPDATE 2-Gambro acquisition boosts Baxter's sales Thursday, 17 Jul 2014 | 1:30 PM ET

    July 17- Medical device and drug maker Baxter International Inc reported higher-than-expected quarterly adjusted earnings, driven primarily by a surge in sales of the dialysis products it gained from its acquisition of Gambro AB last year.

  • The Alzheimer's epidemic: Where we stand Friday, 11 Jul 2014 | 11:45 AM ET

    Although treatments for Alzheimer's have struggled, drugmakers are still working in the space, with 67 medicines currently in development.